98%
921
2 minutes
20
Objectives: Accumulating evidence suggests that stressful life events are associated with increased risk for aggressive behavior in adolescents; however, aggressive reactions to life stressors exhibit large individual differences. The present study sought to examine whether the interaction between a single nucleotide polymorphism (SNP [rs53576]) within the oxytocin receptor gene (OXTR) and stressful life events is related to aggression in Chinese Han adolescents.
Methods: A total of 197 Chinese Han adolescents (14-17 years of age) were included in this study. Aggression was assessed using the 12-item short version of Buss and Perry Aggression Questionnaire. Stressful life events during the past 12 months were assessed using the Adolescent Self-Rating Life Events Checklist. Genomic DNA was extracted from saliva and buccal cells from each individual.
Results: Multivariate analysis of variance yielded a significant interaction between OXTR rs53576 SNP and life stress (F = 2.449, p = 0.043, partial η2 = 0.051) and of sex × SNP × life stress (F = 3.144, p = 0.016, partial η2 = 0.064). High life stress during the past 12 months was associated with high levels of physical aggression and hostility in OXTR rs53576 homozygous AA adolescents but not in G-carrier adolescents. In boys, homozygous AA individuals in the high life stress group reported significantly higher levels of physical aggression than participants in the other three groups; the interaction, however, was not significant in girls.
Conclusions: This study, which analyzed a specific gene-environment interaction, demonstrated that AA OXTR rs53576 homozygosity may correlate with higher levels of aggression under high life stress conditions with a sample of healthy Chinese Han adolescents. These findings promote the etiological understanding of adolescent aggression, highlighting the complex effect of stressful life events on aggression, and adding evidence supporting the relationship between the oxytocin system and aggressive behavior in adolescents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psyneuen.2018.06.002 | DOI Listing |
Circ Genom Precis Med
September 2025
Feinberg School of Medicine, Northwestern University, Chicago, IL (Z.C., P.G., A.G., G.W.).
Background: Genetic variation contributes to atrial fibrillation (AF), but its impact may vary with age. The Research Program contains whole-genome sequencing of data from 100 574 adult participants with linked electronic health records.
Methods: We assessed clinical, monogenic, and polygenic associations with AF in a cross-sectional analysis, stratified by age: <45 years (n=22 290), 45 to 60 years (n=26 805), and >60 years (n=51 659).
Immunotherapy
September 2025
aGuangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
JDR Clin Trans Res
September 2025
School of Dentistry, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.
Objectives: Socioeconomic status (SES) has a significant effect on the burden of early childhood caries (ECC), yet addressing SES disparities remains challenging. This study aimed to identify and quantify the most impactful mediator linking SES effect to the occurrence of ECC using advanced causal mediation analysis, to inform targeted interventions that reduce SES-related disparities in ECC.
Methods: Data were drawn from the Study of Mothers' and Infants' Life Events, a cohort of 2,182 mother-child dyads recruited from Adelaide's 3 largest public hospitals (2013-2014).
Int J Dermatol
September 2025
Servicio de Dermatología, Hospital Infanta Leonor, Madrid, Spain.
Background: Tildrakizumab has demonstrated high efficacy and a good long-term safety profile, including low malignancy rates, in Phase III trials with 5-year extension. Despite these data, the real-world evidence on patients with psoriasis and a history of cancer is limited.
Objectives: To assess the efficacy and safety of tildrakizumab in a cohort of patients with moderate-to-severe psoriasis and a previous or current history of neoplasia.
Eur J Neurol
September 2025
Pain Treatment and Evaluation Center, CHU Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but the dynamics of its effect in real-life conditions remain poorly characterized.
Objective: To assess BT-A efficacy in a real-world study of patients with focal peripheral NP, over a 1-year follow-up period.